title: Apoptosis in sepsis: a new target for therapeutic exploration.
abstract: The treatment of sepsis and septic shock remains a clinical conundrum, and recent prospective trials with biological response modifiers aimed at the inflammatory response have shown only modest clinical benefit. Recently, interest has shifted toward therapies aimed at reversing the accompanying periods of immune suppression. Studies in experimental animals and critically ill patients have demonstrated that increased apoptosis of lymphoid organs and some parenchymal tissues contributes to this immune suppression, anergy, and organ system dysfunction. During sepsis syndromes, lymphocyte apoptosis can be triggered by the absence of IL-2 or by the release of glucocorticoids, granzymes, or the so-called 'death' cytokines: tumor necrosis factor alpha or Fas ligand. Apoptosis proceeds via auto-activation of cytosolic and/or mitochondrial caspases, which can be influenced by the pro- and anti-apoptotic members of the Bcl-2 family. In experimental animals, not only can treatment with inhibitors of apoptosis prevent lymphoid cell apoptosis; it may also improve outcome. Although clinical trials with anti-apoptotic agents remain distant due in large part to technical difficulties associated with their administration and tissue targeting, inhibition of lymphocyte apoptosis represents an attractive therapeutic target for the septic patient.
authors: Departments of Surgery, University of Florida College of Medicine, Gainesville, Florida 32610, USA.
authors: C
authors: C
authors: Oberholzer
authors: A
authors: A
authors: Oberholzer
authors: M
authors: M
authors: Clare-Salzler
authors: L L
authors: LL
authors: Moldawer
mesh_terms: D017209:Apoptosis; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology; D020169:Caspases / Q000502:physiology; D053222:Fas Ligand Protein; D006801:Humans; D008221:Lymphoid Tissue / Q000473:pathology; D008562:Membrane Glycoproteins / Q000502:physiology*; D008928:Mitochondria / Q000502:physiology; D009504:Neutrophils / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D018805:Sepsis / Q000628:therapy*; D015398:Signal Transduction / Q000502:physiology; D018746:Systemic Inflammatory Response Syndrome / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D019253:Proto-Oncogene Proteins c-bcl-2; D014409:Tumor Necrosis Factor-alpha; D020169:Caspases